Physician profile
Alex Kor
NPI 1922169374
$2,167.13
in general payments reported to CMS, 2019-2025
34 companies · $84.15 in 2025
The $84.15 reported for 2025 was less than what a typical Podiatrist provider received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $46.84 · 2020: $241 · 2021: $518 · 2022: $485 · 2023: $775 · 2024: $17.86 · 2025: $84.15.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $877.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $877.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $344.51 | 2019-2023 | Puraply |
| Nevro Corp. | $278.28 | 2022-2023 | Senza |
| Convatec INC. | $163.44 | 2023 | |
| Grt US Holding, INC. | $161.29 | 2021-2022 | |
| Smith+Nephew, INC. | $140.84 | 2021-2023 | Versajet |
| Cardiovascular Systems INC. | $132.60 | 2021 | |
| Ucb, INC. | $126.79 | 2020-2022 | |
| Paratek Pharmaceuticals, INC. | $94.49 | 2020-2025 | Nuzyra |
| Stryker Corporation | $89.46 | 2020-2023 | Salvation |
| Vertex Pharmaceuticals Incorporated | $55.25 | 2025 | |
| Endo Pharmaceuticals INC. | $44.54 | 2020-2021 | |
| Neurocrine Biosciences, INC. | $43.04 | 2020-2022 | |
| Sumitomo Pharma America, INC. | $38.45 | 2023 | Aptiom |
| Banner Life Sciences, LLC | $36.18 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $34.09 | 2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $33.78 | 2020 | |
| Alexion Pharmaceuticals, INC. | $32.55 | 2022-2023 | Soliris |
| Livanova USA, INC. | $28.76 | 2020-2022 | |
| Almatica Pharma LLC | $23.70 | 2021 | |
| Lundbeck LLC | $23.60 | 2023 | Vyepti |
| Kerecis Limited | $23.31 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Eisai INC. | $21.12 | 2022 | |
| Averitas Pharma INC. | $20.68 | 2023 | Qutenza |
| Laborie Medical Technologies Corp. | $18.61 | 2021 | |
| Impel Pharmaceuticals INC. | $18.45 | 2023 | Trudhesa |
| Integra Lifesciences Corporation | $17.62 | 2019 | |
| Janssen Pharmaceuticals, INC | $16.92 | 2021 | |
| Neurelis, INC. | $16.10 | 2020 | |
| Amneal Pharmaceuticals LLC | $15.85 | 2022 | |
| Acorda Therapeutics, INC | $15.43 | 2021 | |
| Tactile Systems Technology INC | $14.95 | 2023 | Flexitouch Plus, Entre Plus |
| Xeris Pharmaceuticals, INC. | $14.59 | 2023 | Keveyis |
| Csl Behring | $14.36 | 2020 | |
| Paragon 28, INC. | $13.50 | 2023 | Portfolio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alex Kor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.